Editas Medicine To Present Data On LDL Cholesterol–Lowering In Vivo Crispr Gene Editing Medicine At American Heart Association Scientific Sessions
Benzinga Newsdesk 12 months ago
News
Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at the
Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at the upcoming American Heart Association (AHA) Scientific Sessions 2025 to be held November 7-10 in New Orleans, Louisiana.